{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:06Z","timestamp":1792785726425,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tehran University of Medical Sciences","award":["TUMS-91"],"award-info":[{"award-number":["TUMS-91"]}],"id":[{"id":"https:\/\/ror.org\/01c4pz451","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Iranian Nanotechnology Initiative","award":["INI-56736"],"award-info":[{"award-number":["INI-56736"]}]},{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["MUMS-930602"],"award-info":[{"award-number":["MUMS-930602"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ejps.2016.03.009","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T20:01:17Z","timestamp":1457640077000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model"],"prefix":"10.1016","volume":"86","author":[{"given":"Masoumeh","family":"Zahmatkeshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Gheybi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Rezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.03.009_bb0005","first-page":"1537","article-title":"Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs","volume":"9","author":"Accardo","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2016.03.009_bb0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1535-7163.MCT-08-0652","article-title":"Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer","volume":"8","author":"Afshar","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2016.03.009_bb0015","first-page":"1484","article-title":"Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice","volume":"53","author":"Ahmad","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/bip.10257","article-title":"Therapeutic cancer targeting peptides","volume":"66","author":"Aina","year":"2002","journal-title":"Pept. Sci."},{"key":"10.1016\/j.ejps.2016.03.009_bb0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2016.03.009_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.03.009_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1081\/LPR-120004771","article-title":"Adventures in targeting","volume":"12","author":"Allen","year":"2002","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2013.10.018","article-title":"Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas","volume":"458","author":"Amin","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.03.009_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2015.10.044","article-title":"Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin","volume":"220","author":"Arabi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0050","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdg365","article-title":"Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer","volume":"14","author":"Atalay","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0055","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejps.2016.03.009_bb0060","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2016.03.009_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/path.1354","article-title":"The clinical evaluation of HER-2 status: which test to use?","volume":"199","author":"Bartlett","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0070","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1074\/jbc.271.9.5251","article-title":"All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired","volume":"271","author":"Baulida","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2016.03.009_bb0075","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1021\/jm000527m","article-title":"Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure\u2013function analysis","volume":"44","author":"Berezov","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2016.03.009_bb0080","doi-asserted-by":"crossref","first-page":"28330","DOI":"10.1074\/jbc.M202880200","article-title":"Disabling receptor ensembles with rationally designed interface peptidomimetics","volume":"277","author":"Berezov","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2016.03.009_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-1119(94)00534-Y","article-title":"Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment","volume":"159","author":"Berns","year":"1995","journal-title":"Gene"},{"key":"10.1016\/j.ejps.2016.03.009_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08982109409037057","article-title":"Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes","volume":"4","author":"Bolotin","year":"1994","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2012.09.033","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"64","author":"Brannon-Peppas","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.03.009_bb0100","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138161210790963788","article-title":"Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications","volume":"16","author":"Brown","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2016.03.009_bb0105","series-title":"Seminars in cell & developmental biology","first-page":"961","article-title":"Targeting erbB receptors","author":"Cai","year":"2010"},{"key":"10.1016\/j.ejps.2016.03.009_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083239","article-title":"Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models","volume":"8","author":"Chang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2016.03.009_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00095-1","article-title":"Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy","volume":"31","author":"Chari","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.03.009_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/17425240902780166","article-title":"Ligand-based targeted therapy for cancer tissue","volume":"6","author":"Das","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2016.03.009_bb0130","first-page":"3320","article-title":"In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma","volume":"58","author":"de Menezes","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0135","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0140","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1158\/0008-5472.CAN-05-0395","article-title":"A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells","volume":"65","author":"Fantin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0145","first-page":"3","article-title":"Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization","author":"Gao","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2016.03.009_bb0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/dna.2005.24.351","article-title":"HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand","volume":"24","author":"Guillemard","year":"2005","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","article-title":"Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases","volume":"1151","author":"Haran","year":"1993","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejps.2016.03.009_bb0160","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1073\/pnas.80.5.1377","article-title":"Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate","volume":"80","author":"Heath","year":"1983","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2016.03.009_bb0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","article-title":"Dimerization of cell surface receptors in signal transduction","volume":"80","author":"Heldin","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2016.03.009_bb0170","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/ja8065557","article-title":"Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties","volume":"130","author":"Huang","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2016.03.009_bb0175","first-page":"5135","article-title":"Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice","volume":"52","author":"Huang","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0180","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1002\/ange.200900111","article-title":"Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery","volume":"121","author":"Huang","year":"2009","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejps.2016.03.009_bb0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0005-2736(01)00357-1","article-title":"In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach","volume":"1513","author":"Iden","year":"2001","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejps.2016.03.009_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-5793(99)01320-4","article-title":"A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs","volume":"460","author":"Ishida","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejps.2016.03.009_bb0195","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1023\/A:1010960900254","article-title":"Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo","volume":"18","author":"Ishida","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0200","first-page":"3981","article-title":"Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging","volume":"7","author":"Jie","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2016.03.009_bb0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/08982109209010212","article-title":"Long-circulating liposomes: development and perspectives","volume":"2","author":"Kiibanov","year":"1992","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0210","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08982109909024786","article-title":"Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells","volume":"9","author":"Lopes de Menezes","year":"1999","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0225","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2016.03.009_bb0230","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.1158\/0008-5472.CAN-05-1093","article-title":"Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo","volume":"65","author":"Mamot","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020138622686","article-title":"PEG-immunoliposome","volume":"22","author":"Maruyama","year":"2002","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejps.2016.03.009_bb0240","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2217\/nnm.12.160","article-title":"EGF receptor-targeted nanocarriers for enhanced cancer treatment","volume":"7","author":"Master","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2016.03.009_bb0245","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1038\/sj.onc.1209745","article-title":"AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2\/neu","volume":"25","author":"Masuda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejps.2016.03.009_bb0250","series-title":"Epidermal Growth Factor Receptor Targeting in Cancer","first-page":"369","author":"Mendelsohn","year":"2006"},{"key":"10.1016\/j.ejps.2016.03.009_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2006.06.014","article-title":"Polymeric conjugates of mono-and bi-cyclic \u03b1 V \u03b2 3 binding peptides for tumor targeting","volume":"114","author":"Mitra","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-5793(91)80699-4","article-title":"Influence of the steric barrier activity of amphipathic poly (ethyleneglycol) and ganglioside GM 1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo","volume":"284","author":"Mori","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejps.2016.03.009_bb0270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ijc.2910450314","article-title":"Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues","volume":"45","author":"Natali","year":"1990","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2016.03.009_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14728222.8.4.335","article-title":"Development of ligand-targeted liposomes for cancer therapy","volume":"8","author":"Noble","year":"2004","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejps.2016.03.009_bb0280","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/72651","article-title":"Rationally designed anti-HER2\/neu peptide mimetic disables P185HER2\/neu tyrosine kinases in vitro and in vivo","volume":"18","author":"Park","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0285","first-page":"1172","article-title":"Anti-HER2 immunoliposomes enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0290","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1158\/0008-5472.CAN-06-2117","article-title":"Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy","volume":"66","author":"Pastorino","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tibtech.2008.06.007","article-title":"Does a targeting ligand influence nanoparticle tumor localization or uptake?","volume":"26","author":"Pirollo","year":"2008","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0300","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/jps.21270","article-title":"Nanovehicular intracellular delivery systems","volume":"97","author":"Prokop","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.03.009_bb0305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","article-title":"Ligand-targeted liposomal anticancer drugs","volume":"42","author":"Sapra","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0310","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/156720105774370159","article-title":"Ligand-targeted liposomes for cancer treatment","volume":"2","author":"Sapra","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejps.2016.03.009_bb0315","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2016.03.009_bb0320","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nprot.2006.4","article-title":"Tricine\u2013SDS-PAGE","volume":"1","author":"Sch\u00e4gger","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejps.2016.03.009_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1410001","article-title":"Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors","volume":"141","author":"Schally","year":"1999","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(03)00240-2","article-title":"Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin","volume":"91","author":"Schiffelers","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0340","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-05-1566","article-title":"Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models","volume":"12","author":"Schluep","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0345","first-page":"469","article-title":"Recent improvements in the use of synthetic peptides for a selective photodynamic therapy","volume":"6","author":"Schneider","year":"2006"},{"key":"10.1016\/j.ejps.2016.03.009_bb0350","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.drup.2003.11.002","article-title":"Selective targeting of cancer cells using synthetic peptides","volume":"6","author":"Shadidi","year":"2003","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ejps.2016.03.009_bb0355","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1016\/j.biomaterials.2011.03.061","article-title":"Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel","volume":"32","author":"Shahin","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2016.03.009_bb0360","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.biomaterials.2013.02.019","article-title":"Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity","volume":"34","author":"Shahin","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2016.03.009_bb0365","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejps.2016.03.009_bb0370","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0375","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-05-2747","article-title":"Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide","volume":"66","author":"Tan","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0380","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","article-title":"RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature","volume":"8","author":"Temming","year":"2005","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ejps.2016.03.009_bb0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2016.03.009_bb0390","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","article-title":"Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status","volume":"65","author":"van der Meel","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.03.009_bb0395","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2007.05.001","article-title":"De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure","volume":"45","author":"Wang","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/723798","article-title":"Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy","author":"Wu","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0405","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11095-005-4588-x","article-title":"Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo","volume":"22","author":"Xiong","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.03.009_bb0410","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2005.03.030","article-title":"Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic","volume":"107","author":"Xiong","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.03.009_bb0415","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/modpathol.3880503","article-title":"Amplification of Her-2\/neu gene in Her-2\/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material","volume":"15","author":"Xu","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejps.2016.03.009_bb0420","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejps.2016.03.009_bb0425","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2011.10.023","article-title":"Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates","volume":"159","author":"Zhang","year":"2012","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716300628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716300628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:46:07Z","timestamp":1760528767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716300628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":85,"alternative-id":["S0928098716300628"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.03.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}